Skip to main content
. 2011 May 10;5(5):e1044. doi: 10.1371/journal.pntd.0001044

Table 1. Demographic and baseline clinical features of the three study groups.

Characteristics Albendazol(N = 30) Ivermectin-I(N = 31) Ivermectin –II(N = 29) P-value
Male: female 21∶9 21∶10 19∶10 0.934
Median (range) age, yr 54 (23–81) 51 (29–77) 52 (25–78) 0.273
Median (range) weight, kg 59 (37–80) 57 (37–85) 59 (44–73) 0.75
Concomitant illnesses, n (%) 0.607
- None 1 0 0
- Diabetes mellitus 8 6 5
- NS/SLE 4 5 4
- AIDS/HIV infection 3 2 5
- Hematological malignancy 2 3 4
- Solid tumor 3 1 6
- Rheumatologic diseases 2 1 1
- Chronic kidney disease 3 2 2
- Alcohol drinker 3 1 1
- Others 6 12 4
Immunosuppressive drug, n (%) 10 (33.3) 11(35.5) 11 (37.9) 0.934
Concomitant parasitoses* 0.380
- Hookworm infection 2 1 0
- Opisthorchiasis 2 1 2
- Enterobious infection 0 1 0
- Entamoeba histolytica infection 0 1 0
- Isospora belli infection 0 0 1

*Diagnosis obtained by ova or cyst found from fecal examination.